Estatísticas Básicas
| CIK | 1712762 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to bioAffinity Technologies, Inc.
SEC Filings (Chronological Order)
Esta página fornece uma lista completa e cronológica de Arquivamentos da SEC, excluindo os arquivamentos de propriedade que fornecemos em outro lugar.
| June 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commis |
|
| June 2, 2026 |
Exhibit 99.1 Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar Interventional pulmonologist, medical oncologist and thoracic surgeon will discuss how CyPath® Lung results have made a critical difference in their practices CyPath® Lung has demonstrated the ability to a |
|
| May 27, 2026 |
Exhibit 99.1 bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology Strong intellectual property portfolio helps build shareholder value Patent strategy protects CyPath® Lung’s flow cytometry-driven diagnostic approach in international markets SAN ANTONIO, Texas – May 27, 2026 – bioAffinity Technologies, |
|
| May 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commis |
|
| May 20, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 bioAffinity Technologies, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.007 par value Other 933,334 $ 1.76 $ 1,642,667.84 0.0001381 $ 226.85 Total Offering A |
|
| May 20, 2026 |
As filed with the Securities and Exchange Commission on May 20, 2026 As filed with the Securities and Exchange Commission on May 20, 2026 Commission File No. |
|
| May 14, 2026 |
497,483 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-295465 PROSPECTUS 497,483 Shares of Common Stock The selling stockholders named in this prospectus may use this prospectus to offer and resell from time to time up to 497,483 shares of our common stock, par value $0.007 per share (“Common Stock”), which are comprised of (i) 365,603 shares of Common Stock (the “Warrant Shares”) issuabl |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commis |
|
| May 12, 2026 |
Exhibit 99.1 bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 CyPath® Lung unit sales in April increased nearly 300% compared to April 2025 Increasing unit sales for CyPath® Lung continues first quarter 2026 trend of accelerating adoption and clinical use Noninvasive test has potential to transform lung cancer risk assessme |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 001-41463 bioAffinit |
|
| May 8, 2026 |
Exhibit 99.1 bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung CyPath® Lung cancer diagnostic unit sales rise 146% year-over-year Growth expected to accelerate throughout 2026 as planned commercial initiatives seek to drive increasing awareness of CyPath® Lung benefits SAN ANTONIO, Texas – May 8, 2026 – bioAffinity Technologies, I |
|
| May 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2026 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commiss |
|
| April 30, 2026 |
Calculation of Filing Fee Tables S-1 bioAffinity Technologies, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forw |
|
| April 30, 2026 |
FIRST AMENDMENT BIOAFFINITY TECHNOLOGIES, INC. 2024 EQUITY INCENTIVE COMPENSATION PLAN Exhibit 10.1 FIRST AMENDMENT TO BIOAFFINITY TECHNOLOGIES, INC. 2024 EQUITY INCENTIVE COMPENSATION PLAN This First Amendment (this “Amendment”) of the bioAffinity Technologies, Inc. 2024 Equity Incentive Plan (the “Plan”) is effective as of April 30, 2026. All terms used but not defined herein shall have the meaning set forth in the Plan. RECITALS WHEREAS, the Board of Directors (the “Board”) appro |
|
| April 30, 2026 |
As filed with the U.S. Securities and Exchange Commission on April 30, 2026 As filed with the U.S. Securities and Exchange Commission on April 30, 2026 Registration Statement No. 333- [*] UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction of incorpor |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 30, 2026 Date of Report (Date of earliest event reported) bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| April 14, 2026 |
Exhibit 99.1 New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy Standard-of-care imaging and risk models indicated cancer after lung screening revealed 30-millimeter pulmonary nodule CyPath® Lung test affirmed physician’s assessment that the nodule could be inflammation, not cancer; nodule resol |
|
| April 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Comm |
|
| April 7, 2026 |
Exhibit 99.1 bioAffinity Technologies’ CyPath® Lung to be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16 Invitation-only conference focuses on the evolving landscape of lung cancer risk and early detection when the disease is most treatable bioAffinity Technologies Chief Medical Officer Gordon Downie, MD, PhD, to participate in panel on lung nodule |
|
| April 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| April 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| April 1, 2026 |
Exhibit 99.1 News Release bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026 Noninvasive diagnostic continues to gain traction in the current and expanding U.S. addressable market of $3.58 billion for pulmonary nodule management and surveillance of lung cancer survivors Flow cytometry+AI technology has potential to improve lung cancer risk assessment and n |
|
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Comm |
|
| March 26, 2026 |
Exhibit 99.1 |
|
| March 25, 2026 |
Exhibit 99.1 bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice Panel of leading pulmonologists will share real-world patient cases and benefits of clinical use of the noninvasive CyPath® Lung diagnostic test First of “CyPath® Lung in Practice” webinar series focuses on need for greater certainty when diagnosing indeterminate pulm |
|
| March 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Comm |
|
| March 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Comm |
|
| March 17, 2026 |
Exhibit 99.1 New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures CyPath® Lung improves diagnostic clarity in patients with multiple lung nodules In this case study, CyPath® Lung “Unlikely Malignancy” result supported physician’s decision to wait before ordering an invasive lung biopsy In a clinical study, noninvasiv |
|
| March 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to . Commission file number 001-41463 bioAffinity Tech |
|
| March 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to . Commission file number 001-41463 bioAffinity Tech |
|
| March 13, 2026 |
Exhibit 99.1 bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company’s high-value CyPath® Lung test Number of CyPath® Lung tests performed in 2025 increased by 99% compared to 2024 Orders for CyPath® Lung by physicians and c |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2026 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Comm |
|
| March 10, 2026 |
Exhibit 99.1 bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic Study to evaluate clinical performance of CyPath® Lung for the early detection of lung cancer in high-risk patients Murtha Cancer Center Research Program at Uniformed Services University of the Health Sciences provides support for longitudinal stu |
|
| March 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Comm |
|
| March 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| March 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 3, 2026 |
Exhibit 99.1 bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAI) Annual Meeting Research demonstrates the technology’s ability to identify drug antibody receptors in spu |
|
| March 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| March 3, 2026 |
Exhibit 99.2 |
|
| February 25, 2026 |
Exhibit 99.1 bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung SAN ANTONIO, TX – February 25, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), |
|
| February 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| February 19, 2026 |
Exhibit 99.1 New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer CyPath® Lung test supported recommendation for surveillance strategy, rather than subjecting elderly patient to an invasive, risky and costly biopsy procedure Despite a suspicious nodule during a low-dose CT scan, a repeat scan showed no nodules |
|
| February 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| February 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| February 17, 2026 |
Exhibit 99.1 Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study Noninvasive CyPath® Lung test has shown 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules less than 2 centimeters Case study highlights how CyPath® Lung reduces patient anxiety and supports physician confidence in assessment of benign pulmona |
|
| February 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| February 10, 2026 |
Exhibit 99.1 |
|
| February 9, 2026 |
Exhibit 99.1 bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board Advisory Board provides independent guidance on strategic priorities, including growing adoption of the Company’s noninvasive CyPath® Lung diagnostic test SAN ANTONIO, TX – February 9, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a |
|
| February 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Co |
|
| February 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Co |
|
| January 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2026 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| January 7, 2026 |
Exhibit 99.1 News Release bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation CyPath® Lung addresses urgent unmet need in projected $10.4 billion lung cancer diagnostic market by 2034 Precision Pathology Laboratory Services meets gold standard for excellence across all laboratory service lines CAP accreditation reaffirms CyPath® Lung test |
|
| December 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| December 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| December 3, 2025 |
Exhibit 99.1 bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable SAN ANTONIO, Texas – December 3, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer Gordon Downie, MD, |
|
| December 3, 2025 |
Exhibit 99.2 |
|
| December 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Co |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-41463 bioAff |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| November 14, 2025 |
Exhibit 99.1 bioAffinity Technologies Reports Third Quarter 2025 Financial Results Company achieves 86% increase in CyPath® Lung testing revenue, strengthens balance sheet SAN ANTONIO, Texas – November 14, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of early-stage lung cancer and other lung diseases, toda |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| November 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Co |
|
| November 5, 2025 |
Exhibit 99.1 bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume October test volume 111% more than 2025 year-to-date monthly average SAN ANTONIO, Texas — November 5, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced continued s |
|
| October 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Co |
|
| October 28, 2025 |
Exhibit 99.1 bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases Australian patent strengthens global patent portfolio SAN ANTONIO, TX — October 28, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics including CyPath® Lung, the Company’s noni |
|
| October 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| October 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Co |
|
| October 20, 2025 |
Exhibit 99.2 |
|
| October 20, 2025 |
Exhibit 99.1 bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025 Visit the CyPath® Lung team at Booth #2242 October 19-22 SAN ANTONIO, Texas – October 20, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced it will present resea |
|
| October 16, 2025 |
Exhibit 99.1 bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer U.S. award protects AI-built platform and adds to growing international patent portfolio SAN ANTONIO, TX — October 16, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diag |
|
| October 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Co |
|
| October 15, 2025 |
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements Exhibit 99.1 bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements SAN ANTONIO, TX — October 15, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung cancer, today announced that it has received a written notice from |
|
| October 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Co |
|
| October 9, 2025 |
720,000 Shares of Common Stock bioAffinity Technologies, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-275608 Prospectus Supplement (to Prospectus dated November 27, 2023) 720,000 Shares of Common Stock bioAffinity Technologies, Inc. We are offering 720,000 shares of our common stock, $0.007 par value per share (the “common stock”), directly to institutional investors pursuant to this prospectus supplement and the accompanying prospectus. The pe |
|
| October 9, 2025 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT October 8, 2025 bioAffinity Technologies Inc. 3300 Nacogdoches Road, Suite 216 SanAntonio, TX 78217 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), bioAffinity Technologies Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $1,800,000 of registered securities of the Company, consistin |
|
| October 9, 2025 |
Exhibit 99.2 News Release bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules SAN ANTONIO, Texas (October 9, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has clo |
|
| October 9, 2025 |
Exhibit 99.1 News Release bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules SAN ANTONIO, Texas (October 8, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it |
|
| October 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| October 9, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of October 8, 2025, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “ Purchasers”). RE |
|
| October 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| October 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| October 7, 2025 |
bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025 Exhibit 99.1 bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025 SAN ANTONIO, TX – October 7, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced sales of its CyPath® Lung diagnostic test for lung cancer reached a new high in the |
|
| September 30, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Warrant Shares: Issue Date: THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the |
|
| September 30, 2025 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-290480 PROSPECTUS bioAffinity Technologies, Inc. 1,047,694 Shares of Common Stock 874,067 Pre-Funded Warrants to Purchase Shares of Common Stock Up to 874,067 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering 1,047,694 shares of our Common Stock, $0.007 par value per share (the “Common Stock”). The public offering price |
|
| September 30, 2025 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT September 29, 2025 bioAffinity Technologies Inc. 3300 Nacogdoches Road, Suite 216 San Antonio, TX 78217 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), bioAffinity Technologies Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of up to $4,798,284.03 of registered securities of the Compa |
|
| September 30, 2025 |
bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering Exhibit 99.1 bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering SAN ANTONIO, TX – September 29, 2025 – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has priced a public offering of securities as described below for aggregate gross proceed |
|
| September 30, 2025 |
bioAffinity Technologies Announces Closing of $4.8 Million Public Offering Exhibit 99.2 bioAffinity Technologies Announces Closing of $4.8 Million Public Offering SAN ANTONIO, Texas (September 30, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced the closing of its previously announced public offering of securities as described below for a |
|
| September 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) ( |
|
| September 30, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of September 29, 2025, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). |
|
| September 29, 2025 |
X0101 EFFECT 33 LIVE 2025-09-29 15:00:00 S-1 0001712762 bioAffinity Technologies, Inc. 333-290480 |
|
| September 26, 2025 |
bioAffinity Technologies, Inc. 3300 Nacogdoches Road, Suite 216 San Antonio, Texas 78217 (210) 698-5334 September 26, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Sawicki Re: bioAffinity Technologies, Inc. Registration Statement on Form S-1 Filed September 22, 2025 File No. 333-290480 Ladies and Gentlemen: Pursuant to |
|
| September 26, 2025 |
bioAffinity Technologies, Inc. 3300 Nacogdoches Road, Suite 216 San Antonio, Texas 78217 (210) 698-5334 September 26, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Sawicki Re: bioAffinity Technologies, Inc. Registration Statement on Form S-1 Filed September 22, 2025 File No. 333-290480 Ladies and Gentlemen: bioAffinity |
|
| September 25, 2025 |
As filed with the Securities and Exchange Commission on September 25, 2025. As filed with the Securities and Exchange Commission on September 25, 2025. Registration No. 333-290480 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction |
|
| September 25, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-1 (Form Type) BIOAFFINITY TECHNOLOGIES, INC. |
|
| September 24, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-1 (Form Type) BIOAFFINITY TECHNOLOGIES, INC. |
|
| September 24, 2025 |
FORM OF COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Exhibit 4.22 FORM OF COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Warrant Shares: Issue Date: [*], 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issuance Date (the |
|
| September 24, 2025 |
Exhibit 4.25 bioAffinity Technologies, Inc. and VStock Transfer, LLC, as Warrant Agent Warrant Agent Agreement FORM OF WARRANT AGENT AGREEMENT This WARRANT AGENT AGREEMENT (this “Warrant Agreement”), dated as of [ ], 2025 (the “Initial Exercise Date”) is between bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), and VStock Transfer, LLC, a California limited liability company |
|
| September 24, 2025 |
Exhibit 10.50 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [*], 2025, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS |
|
| September 24, 2025 |
Exhibit 10.51 PLACEMENT AGENCY AGREEMENT [*], 2025 bioAffinity Technologies Inc. 3300 Nacogdoches Road, Suite 216 San Antonio, TX 78217 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), bioAffinity Technologies Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of up to $[*] of registered securities of the Company, consisting o |
|
| September 24, 2025 |
PLACEMENT AGENT WARRANT BIOAFFINITY TECHNOLOGIES, INC. Exhibit 4.24 PLACEMENT AGENT WARRANT BIOAFFINITY TECHNOLOGIES, INC. Warrant Shares: Issue Date: , 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [*], 2025 (the “Initial Exercise Date”) and |
|
| September 24, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Exhibit 4.23 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Warrant Shares: Issue Date: THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (th |
|
| September 24, 2025 |
As filed with the Securities and Exchange Commission on September 24, 2025. As filed with the Securities and Exchange Commission on September 24, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction of incorporation or organ |
|
| September 24, 2025 |
bioAffinity Technologies, Inc. 3300 Nacogdoches Road, Suite 216 San Antonio, Texas 78217 (210) 698-5334 September 24, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Sawicki Re: bioAffinity Technologies, Inc. Registration Statement on Form S-1 Filed September 24, 2025 File No. 333-290480 Ladies and Gentlemen: Pursuant to |
|
| September 18, 2025 |
bioAffinity Technologies, Inc. 32,495,628 Shares of Common Stock PROSPECTUS Filed Pursuant to 424(b)(3) Registration Statement No. 333-289944 bioAffinity Technologies, Inc. 32,495,628 Shares of Common Stock This prospectus relates to the resale from time to time of up to 32,495,628 shares of common stock, par value $0.007 per share (the “Common Stock”), of bioAffinity Technologies, Inc. by the Selling Stockholders identified in this prospectus (the “Selling Sto |
|
| September 17, 2025 |
FORM OF CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF BIOAFFINITY TECHNOLOGIES, INC. Exhibit 3.1 FORM OF CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF BIOAFFINITY TECHNOLOGIES, INC. bioAffinity Technologies, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Corporation’s Ce |
|
| September 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) ( |
|
| September 17, 2025 |
Exhibit 99.1 bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025 SAN ANTONIO, TX – September 17, 2025 – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-30 reverse split of its |
|
| September 16, 2025 |
X0101 EFFECT 33 LIVE 2025-09-16 16:30:00 S-1 0001712762 bioAffinity Technologies, Inc. 333-289944 |
|
| September 16, 2025 |
bioAffinity Technologies, Inc. 3300 Nacogdoches Road, Suite 216 San Antonio, Texas 78217 (210) 698-5334 September 16, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Robert Augustin Re: bioAffinity Technologies, Inc. Registration Statement on Form S-1 Filed August 29, 2025 File No. 333-289944 Ladies and Gentlemen: Pursuant to Rul |
|
| September 15, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) 333-289944 BIOAFFINITY TECHNOLOGIES, INC. |
|
| September 15, 2025 |
As filed with the Securities and Exchange Commission on September 12, 2025. As filed with the Securities and Exchange Commission on September 12, 2025. Registration No. 333-289944 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction |
|
| September 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| September 9, 2025 |
Exhibit 99.1 Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment SAN ANTONIO, TX – September 9, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnolog |
|
| September 5, 2025 |
Exhibit 99.1 |
|
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| September 3, 2025 |
September 3, 2025 Maria Zannes Chief Executive Officer bioAffinity Technologies, Inc. |
|
| September 3, 2025 |
Exhibit 99.1 U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA Noninvasive diagnostic can help federal medical system address veterans at higher risk for developing lung cancer SAN ANTONIO, TX – September 3, 2025 – U.S. Medicine, a leading publication for federal healthcare professionals, has featured bioAffinity Te |
|
| September 2, 2025 |
BIOAFFINITY TECHNOLOGIES, INC. FIRST AMENDMENT TO WARRANT Exhibit 4.2 BIOAFFINITY TECHNOLOGIES, INC. FIRST AMENDMENT TO WARRANT THIS FIRST AMENDMENT, dated as of September 2, 2025 (this “Amendment”), to that certain Common Stock Purchase Warrant (“Warrant”), dated as of August 13, 2025, issued by bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) to purchase the number of shares of common stock of the Company as set forth on the signa |
|
| September 2, 2025 |
BIOAFFINITY TECHNOLOGIES, INC. SECOND AMENDMENT TO WARRANT Exhibit 4.1 BIOAFFINITY TECHNOLOGIES, INC. SECOND AMENDMENT TO WARRANT THIS SECOND AMENDMENT, dated as of September 2, 2025 (this “Amendment”), to that certain Common Stock Purchase Warrant (“Warrant”), dated as of May 7, 2025, issued by bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) to purchase the number of shares of common stock of the Company as set forth on the signatu |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| August 29, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOAFFINITY TECHNOLOGIES, INC. |
|
| August 29, 2025 |
As filed with the Securities and Exchange Commission on August 29, 2025. As filed with the Securities and Exchange Commission on August 29, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction of incorporation or organiza |
|
| August 26, 2025 |
August 26, 2025 Maria Zannes Chief Executive Officer bioAffinity Technologies, Inc. |
|
| August 22, 2025 |
As confidentially submitted on August 22, 2025 to the Securities and Exchange Commission pursuant to Section 106(a) of the Jumpstart Our Business Startups Act of 2012. |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| August 18, 2025 |
Exhibit 99.1 bioAffinity Technologies Appoints New Members to Board of Directors Financial and Clinical Leaders Provide Significant Expertise for the Company’s Commercial Growth SAN ANTONIO, Texas (August 18, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company advancing noninvasive diagnostics for the early detection of lung cancer and other diseases, today announ |
|
| August 14, 2025 |
Exhibit 99.1 bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds SAN ANTONIO, Texas (August 13, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into |
|
| August 14, 2025 |
Form of Warrant Inducement Agreement Exhibit 10.3 August 11, 2025 To: Holder of Common Share Purchase Warrants Re: Inducement Offer and Agreement to Exercise Common Share Purchase Warrants Dear Holder: bioAffinity Technologies Inc., a Delaware corporation (the “Company”), is pleased to offer to you the opportunity to exercise the 450,000 Common Stock Purchase Warrants issued to you on August 5, 2024 (with a current exercise price of |
|
| August 14, 2025 |
Exhibit 99.1 bioAffinity Technologies Reports Second Quarter 2025 Results CyPath® Lung revenues up 62% year-over-year in first six months of 2025 SAN ANTONIO, Texas (August 14, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of early-stage lung cancer and other lung diseases, today reported financial results |
|
| August 14, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of August 13, 2025, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). REC |
|
| August 14, 2025 |
Exhibit 99.2 bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds SAN ANTONIO, Texas (August 14, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced the closing of its prev |
|
| August 14, 2025 |
Form of Placement Agent Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 14, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 14, 2025 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-41463 bioAffinity |
|
| August 14, 2025 |
Financial Advisory Agreement dated August 13, 2025 Exhibit 10.4 August 13, 2025 Maria Zannes President and Chief Executive Officer bioAffinity Technologies Inc. 3300 Nacogdoches Suite 216 San Antonio, TX 78217 Re: General Financial Advisory Dear Ms. Zannes, This letter (the “Agreement”) will confirm our understanding that the company known to us as bioAffinity Technologies Inc. (“bioAffinity”, or the “Company”) has engaged WallachBeth Capital LLC |
|
| August 14, 2025 |
Certificate of Amendment to the Certificate of Incorporation Exhibit 3.1 FORM OF CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF BIOAFFINITY TECHNOLOGIES, INC. bioAffinity Technologies, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Corporation’s Ce |
|
| August 14, 2025 |
Placement Agency Agreement dated August 13, 2025 Exhibit 1.1 PLACEMENT AGENCY AGREEMENT August 13, 2025 bioAffinity Technologies Inc. 33000 Nacogdoches Road, Suite 216 San Antonio, TX 78217 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), bioAffinity Technologies Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $950,000 of unregistered securities of the Company, includi |
|
| August 14, 2025 |
Exhibit 4.4 BIOAFFINITY TECHNOLOGIES, INC. FIRST AMENDMENT TO WARRANT THIS FIRST AMENDMENT, dated as of August 13, 2025 (this “Amendment”), to that certain Common Stock Purchase Warrant (“Warrant”), dated as of May 7, 2025, issued by bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) to purchase in aggregate [*] shares of common stock of the Company is between the Company and e |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| August 14, 2025 |
Certificate of Designations of Series B Convertible Preferred Stock Exhibit 3.2 BIOAFFINITY TECHNOLOGIES, INC. CERTIFICATE OF DESIGNATIONS OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware, bioAffinity Technologies, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), in accordance with t |
|
| August 14, 2025 |
Form of Registration Rights Agreement Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is entered into and made effective as of August 13, 2025, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). The |
|
| August 13, 2025 |
Exhibit 99.1 bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales July Test Volume Surges 72% Over Prior Monthly Average SAN ANTONIO, TX – August 13, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a significant surge in commercial sales of its flagship pro |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Comm |
|
| July 31, 2025 |
Exhibit 99.1 Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging and Low-Risk Serum Test Results bioAffinity Technologies’ noninvasive sputum test catches rare cancer in time for curative surgery SAN ANTONIO, TX – July 29, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and earl |
|
| July 31, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 25, 2025 Date of Report (Date of earliest event reported) bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commis |
|
| July 23, 2025 |
Exhibit 99.1 Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools bioAffinity Technologies’ noninvasive sputum test flagged difficult-to-diagnose cancer at earliest Stage 1A SAN ANTONIO, TX – July 23, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive, accurate tests for the detection of early-s |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| July 22, 2025 |
Exhibit 99.1 Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths SAN ANTONIO, TX — July 22, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath |
|
| July 15, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| July 15, 2025 |
Exhibit 99.1 bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic Nearly one-third of world’s smokers live in China, which has one of the highest rates of lung cancer SAN ANTONIO, TX — July 15, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPa |
|
| June 27, 2025 |
As filed with the Securities and Exchange Commission on June 27, 2025. As filed with the Securities and Exchange Commission on June 27, 2025. Registration No. 333-264463 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT NO. 333-264463 UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (Sta |
|
| June 27, 2025 |
As filed with the Securities and Exchange Commission on June 27, 2025. As filed with the Securities and Exchange Commission on June 27, 2025. Registration No. 333-283521 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT NO. 333-283521 UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (Sta |
|
| June 2, 2025 |
2024 Annual Report to Shareholders bioAffinity Technologies, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. OR տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transitio |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| May 30, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commis |
|
| May 27, 2025 |
Up to $5,801,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-275608 PROSPECTUS SUPPLEMENT (To Prospectus dated November 27, 2023) Up to $5,801,000 Shares of Common Stock We have entered into an At-the-Market Issuance Sales Agreement, dated May 22, 2025 (the “Sales Agreement”), with WallachBeth Capital LLC (“WallachBeth” or the “Sales Agent”) relating to the sale of shares of our common stock, par value $ |
|
| May 27, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commis |
|
| May 27, 2025 |
Exhibit 1.1 BIOAFFINITY TECHNOLOGIES, INC. Common Stock (par value $0.007 per share) At-The-Market Issuance Sales Agreement May 22, 2025 WallachBeth Capital LLC 185 Hudson St Jersey City, NJ 07302 Ladies and Gentlemen: bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with WallachBeth Capital LLC (the “Agent”), as follows: 1. Issuance |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| May 19, 2025 |
Other Events, Shareholder Director Nominations, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 001-41463 bioAffinit |
|
| May 15, 2025 |
Exhibit 99.1 bioAffinity Technologies Reports First Quarter 2025 Results CyPath® Lung sales up 276% year-over-year SAN ANTONIO, Texas (May 15, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for accurate, noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three mo |
|
| May 8, 2025 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT May 5, 2025 bioAffinity Technologies Inc. 3300 Nacogdoches Road, Suite 216 San Antonio, TX 78217 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), bioAffinity Technologies Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of up to $3,239,828.17 of registered securities of the Company, con |
|
| May 8, 2025 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commiss |
|
| May 8, 2025 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Warrant Shares: Issue Date: May 7, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| May 8, 2025 |
bioAffinity Technologies Announces Pricing of $3.25 Million Offering Exhibit 99.1 bioAffinity Technologies Announces Pricing of $3.25 Million Offering SAN ANTONIO, Texas (May 6, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has priced a best efforts offering of securities as described below for aggregate gross proceeds to |
|
| May 8, 2025 |
Exhibit 4.2 FORM OF COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Warrant Shares: Issue Date: May 7, 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issuance Date (th |
|
| May 8, 2025 |
bioAffinity Technologies Announces Closing of $3.25 Million Offering Exhibit 99.2 bioAffinity Technologies Announces Closing of $3.25 Million Offering SAN ANTONIO, Texas (May 7, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has closed its previously announced best efforts offering of securities as described below for aggr |
|
| May 8, 2025 |
Form of Placement Agent Warrant Exhibit 4.3 IN ACCORDANCE WITH FINRA RULE 5110(E), THE REGISTERED HOLDER OF THIS COMMON STOCK PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER, OR ASSIGN THIS COMMON STOCK PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS COMMON STOCK PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE, OR HYPOTHECATE THIS COMMON STOCK |
|
| May 8, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of May 5, 2025, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). |
|
| May 7, 2025 |
PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-286921 Up to 7,784,904 Shares of Common Stock Pre-Funded Warrants to Purchase up to 2,371,346 Shares of Common Stock Warrants to Purchase up to 19,804,687 Shares of Common Stock Placement Agent Warrants to Purchase up to 304,687 Shares of Common Stock Up to 22,480,720 Shares of Common Stock Issuable Upon Exercise of Pre-Funded Warran |
|
| May 5, 2025 |
Exhibit 4.20 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Warrant Shares: Issue Date: THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (th |
|
| May 5, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOAFFINITY TECHNOLOGIES, INC. |
|
| May 5, 2025 |
Exhibit 4.19 FORM OF COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Warrant Shares: Issue Date: [*], 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issuance Date (the |
|
| May 5, 2025 |
As filed with the Securities and Exchange Commission on May 5, 2025. As filed with the Securities and Exchange Commission on May 5, 2025. Registration No. 333-286921 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No.1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction of incor |
|
| May 5, 2025 |
Form of Securities Purchase Agreement Exhibit 10.42 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [*], 2025, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS |
|
| May 2, 2025 |
WallachBeth Capital, LLC Harborside Financial Plaza 5 185 Hudson St., Suite 1410 Jersey City, NJ 07311 May 2, 2025 VIA EDGAR CORRESPONDENCE U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: bioAffinity Technologies, Inc. Registration Statement on Form S-1 File No. 333-286921 REQUEST FOR ACCELERATION OF EFFECTIVENESS Dear Staff: Pu |
|
| May 2, 2025 |
As filed with the Securities and Exchange Commission on May 2, 2025. As filed with the Securities and Exchange Commission on May 2, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction of incorporation or organization |
|
| May 2, 2025 |
Exhibit 4.19 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| May 2, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOAFFINITY TECHNOLOGIES, INC. |
|
| May 2, 2025 |
Form of Securities Purchase Agreement Exhibit 10.42 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [*], 2025, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS |
|
| May 2, 2025 |
Form of Placement Agency Agreement Exhibit 1.4 PLACEMENT AGENCY AGREEMENT May [*], 2025 bioAffinity Technologies Inc. 3300 Nacogdoches Road, Suite 216 San Antonio, TX 78217 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), bioAffinity Technologies Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of up to $[*] of registered securities of the Company, consisting |
|
| May 2, 2025 |
Form of Placement Agent Warrant Exhibit 4.21 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| May 2, 2025 |
Form of Warrant Agent Agreement for the April 2025 Warrants Exhibit 4.22 bioAffinity Technologies, Inc. and VStock Transfer, LLC, as Warrant Agent Warrant Agent Agreement FORM OF WARRANT AGENT AGREEMENT This WARRANT AGENT AGREEMENT (this “Warrant Agreement”), dated as of [ ], 2025 (the “Initial Exercise Date”) is between bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), and VStock Transfer, LLC, a California limited liability company |
|
| May 2, 2025 |
Exhibit 4.20 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Warrant Shares: Issue Date: THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (th |
|
| May 2, 2025 |
May 2, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to . Commission file number 001-4146 |
|
| April 22, 2025 |
bioAffinity Technologies, Inc. 3,013,951 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-286497 PROSPECTUS bioAffinity Technologies, Inc. 3,013,951 Shares of Common Stock This prospectus relates to the resale from time to time of up to 3,013,951 shares of common stock, par value $0.007 per share (the “Common Stock”), of bioAffinity Technologies, Inc. by the Selling Stockholders identified in this prospectus (the “Selling Stockholde |
|
| April 18, 2025 |
April 18, 2025 Maria Zannes Chief Executive Officer bioAffinity Technologies, Inc. |
|
| April 16, 2025 |
April 16, 2025 Maria Zannes Chief Executive Officer bioAffinity Technologies, Inc. |
|
| April 16, 2025 |
April 16, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 15, 2025 |
As confidentially submitted on April [ ], 2025 to the Securities and Exchange Commission. |
|
| April 15, 2025 |
Phone: (212) 885-5358 Fax: (917) 332-3824 Email: [email protected] April 15, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: bioAffinity Technologies, Inc. Draft Registration Statement (DRS) on Form S-1 Submitted on April 15, 2025 CIK No. 0001712762 Dear Sir or Madam: On behalf of our client, bi |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Comm |
|
| April 11, 2025 |
As filed with the Securities and Exchange Commission on April 11, 2025. As filed with the Securities and Exchange Commission on April 11, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction of incorporation or organizat |
|
| April 11, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOAFFINITY TECHNOLOGIES, INC. |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Comm |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to . Commission file number 001-41463 bioAffinity Tech |
|
| March 31, 2025 |
Exhibit 99.1 News Release bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 Increased Demand, Expanded Insurance Coverage Drive Record Growth SAN ANTONIO, Texas (March 31, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, |
|
| March 31, 2025 |
Exhibit 4.13 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED bioAffinity Technologies, Inc. (the “Company,” “we,” “us,” and “our”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock, par value $0.007 per share (the “Common Stock”), and trad |
|
| March 31, 2025 |
Amended and Restated Insider Trading Policy of the Registrant Exhibit 19.1 bioAffinity Technologies, Inc. Amended and Restated Insider Trading Policy and Guidelines with Respect to Certain Transactions in Company Securities As Adopted by the Board of Directors on March 27, 2025 I. PURPOSE It is illegal for any employee, officer or director of bioAffinity Technologies, Inc. or any subsidiary thereof (the “Company”) to trade in the securities of the Company wh |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Commi |
|
| March 7, 2025 |
Exhibit 99.1 News Release bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth ● Proactive steps reinforce bioAffinity Technologies’ laser focus on accelerating CyPath® Lung sales growth in strategic national markets ● Decreases labor and overhead costs, including 38% workforce reduction in non-CyPath® Lung personnel at Company’s subsid |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 25, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Co |
|
| February 27, 2025 |
Exhibit 10.1 February 25, 2025 To: Holder of Common Share Purchase Warrants Re: Inducement Offer and Agreement to Exercise Common Share Purchase Warrants Dear Holder: bioAffinity Technologies Inc., a Delaware corporation (the “Company”), is pleased to offer to you the opportunity to exercise the [ ] Common Stock Purchase Warrants issued to you on August 5, 2024 (with a current exercise price of $ |
|
| February 27, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 27, 2025 |
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million Exhibit 99.1 bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million SAN ANTONIO, Texas (February 25, 2024) – bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 2,438,473 of the |
|
| February 27, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 25, 2025 |
bioAffinity Technologies, Inc. 1,801,944 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-282045 PROSPECTUS SUPPLEMENT NO. 2 (to the prospectus dated September 19, 2024) bioAffinity Technologies, Inc. 1,801,944 Shares of Common Stock This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form S-1, effective as of September 19, 2024 (as supplemented or amended from time to |
|
| February 25, 2025 |
bioAffinity Technologies, Inc. 2,724,230 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-283521 PROSPECTUS SUPPLEMENT NO. 1 (to the prospectus dated December 6, 2024) bioAffinity Technologies, Inc. 2,724,230 Shares of Common Stock This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form S-1, effective as of December 6, 2024 (as supplemented or amended from time to tim |
|
| February 7, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 7, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| January 14, 2025 |
Exhibit 10.1 AMENDMENT NO.2 TO EMPLOYMENT AGREEMENT This Amendment No. 2 effective as of January 10, 2025 (this “Amendment”), to the Employment Agreement, dated February 1, 2015, as amended by the amendment dated July 27, 2023 (the “Agreement”), is entered into by and between bioAffinity Technologies Inc. (the “Company”) and Maria Zannes (the “Employee”). Capitalized terms used herein without defi |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 10, 2025 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| December 23, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| December 20, 2024 |
Exhibit 99.1 GOOD AFTERNOON – I AM EXCITED TO SPEAK WITH YOU TODAY AND DISCUSS OUR PLANS FOR 2025 AS WELL AS REVIEW THE SUCCESS BIOAFFINITY TECHNOLOGIES HAS ENJOYED THIS YEAR. DURING THIS PRESENTATION, CERTAIN FORWARD-LOOKING STATEMENTS REGARDING BIOAFFINITY TECHNOLOGIES, INC.’S CURRENT EXPECTATIONS AND PROJECTIONS ABOUT FUTURE EVENTS WILL BE MADE. GENERALLY, THE FORWARD-LOOKING STATEMENTS CAN BE |
|
| December 9, 2024 |
bioAffinity Technologies, Inc. 2,724,230 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-283521 PROSPECTUS bioAffinity Technologies, Inc. 2,724,230 Shares of Common Stock This prospectus relates to the resale from time to time of up to 2,724,230 shares of common stock, par value $0.007 per share (the “Common Stock”), of bioAffinity Technologies, Inc. by the Selling Stockholders identified in this prospectus (the “Selling Stockholde |
|
| December 4, 2024 |
December 4, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 4, 2024 |
December 4, 2024 Maria Zannes Chief Executive Officer bioAffinity Technologies, Inc. |
|
| November 27, 2024 |
As filed with the Securities and Exchange Commission on November 27, 2024. As filed with the Securities and Exchange Commission on November 27, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 8731 46-5211056 (State or other jurisdiction of incorporation or organi |
|
| November 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) BIOAFFINITY TECHNOLOGIES, INC. |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| November 22, 2024 |
1,632,000 Shares of Common Stock bioAffinity Technologies, Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-278512 PROSPECTUS SUPPLEMNT NO. 3 1,632,000 Shares of Common Stock bioAffinity Technologies, Inc. This prospectus supplement updates, amends and supplements the prospectus contained in our Amendment No. 1 to Form S-1, effective as of April 15, 2024 (as supplemented or amended from time to time, the “Prospectus”) (Registration No. 333-278512). C |
|
| November 22, 2024 |
1,801,944 Shares of Common Stock bioAffinity Technologies, Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-282045 PROSPECTUS SUPPLEMNT NO. 1 1,801,944 Shares of Common Stock bioAffinity Technologies, Inc. This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form S-1, effective as of September 19, 2024 (as supplemented or amended from time to time, the “Prospectus”) (Registration No. 333 |
|
| November 22, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-264463 PROSPECTUS SUPPLEMNT NO. 3 4,305,813 Shares of Common Stock underlying Tradeable Warrants and Non-Tradeable Warrants and 55,116 Shares of Common Stock underlying Placement Agent Warrants and Representative’s Warrants bioAffinity Technologies, Inc. This prospectus supplement updates, amends and supplements the prospectus contained in our |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 001-41463 bioAff |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (C |
|
| November 14, 2024 |
Exhibit 99.1 bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 Expanded CyPath® Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 states Number of physician offices signed increased 75% over Q2 2024 Reaffirmed $9.6 million 2024 revenue forecast for wholly owned Precision Pathology subsidiary SAN ANTONIO, Texas (November 14 |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| October 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Co |
|
| October 21, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 21, 2024 |
Exhibit 10.2 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”) is made as of October 21, 2024, by and between bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) and the Person set forth on Schedule A hereto (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the beneficial owner of the number of shares of the common stock of the Company set forth o |
|
| October 21, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 21, 2024 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT October 18, 2024 bioAffinity Technologies Inc. 3300 Nacogdoches Road, Suite 216 SanAntonio, TX 78217 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), bioAffinity Technologies Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $2,662,782.20 of registered and unregistered securities of t |
|
| October 21, 2024 |
Exhibit 3.1 BIOAFFINITY TECHNOLOGIES, INC. AMENDMENT TO AMENDED AND RESTATED BY-LAWS This Amendment to the Amended and Restated By-laws (the “By-laws”) of bioAffinity Technologies, Inc. (the “Company”), as adopted by the Board of Directors pursuant to Article VIII of said By-laws and Section 10 of the Company’s Certificate of Incorporation, as amended, is effective as of the 17th day of October, 2 |
|
| October 21, 2024 |
2,048,294 Shares of Common Stock bioAffinity Technologies, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-275608 Prospectus Supplement (to Prospectus dated November 27, 2023) 2,048,294 Shares of Common Stock bioAffinity Technologies, Inc. We are offering 2,048,294 shares of our common stock, $0.007 par value per share (the “common stock”), directly to institutional investors pursuant to this prospectus supplement and the accompanying prospectus. Th |
|
| October 21, 2024 |
Exhibit 99.1 bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement SAN ANTONIO, TX (Oct. 18, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has entered into a securities purchase agreement with i |
|
| October 21, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of October 18, 2024, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RE |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 bioAffinity Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41463 46-5211056 (State or other jurisdiction of incorporation) (Com |
|
| October 10, 2024 |
Exhibit 99.1 News Release bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer Edwards rejoins the Company after serving as interim CFO SAN ANTONIO, TX (Oct. 10, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that J. Michael Edwards has a |
